Background: Hepatitis, characterized by hepatic inflammation, poses a global health threat, particularly in developing nations like Pakistan. Hepatitis B (HBV) and C (HCV) viruses are major contributors, with HBV affecting 2 billion people worldwide. In Pakistan, nearly nine million individuals are infected with HBV, emphasizing the urgency of effective interventions. HCV, impacting around 3% of the global population, poses significant challenges, with ten million affected individuals in Pakistan. This study addresses the need for focused research on HCV treatment, specifically in the context of Sofosbuvir (SOF) and Daclatasvir (DCV) regimens.

Methods: A randomized controlled trial (RCT) compared the effects of two regimens, SOF+DCV and SOF+Ribavirin, in 56 chronic HCV patients aged 18-65. Participants were equally divided, and treatment outcomes, adherence, and adverse events were assessed. Primary outcomes included End-of-Treatment Response (ETR) and Sustained Virological Response (SVR). Statistical analysis considered a p-value < 0.05 as significant.

Results: Both regimens exhibited high adherence rates (SOF+DCV 90%, SOF+Ribavirin 92%) and favorable treatment outcomes (ETR: SOF+DCV 85%, SOF+Ribavirin 80%; SVR: SOF+DCV 80%, SOF+Ribavirin 75%). Adverse events were mild, supporting overall tolerability.

Conclusion: This RCT provides valuable insights into the efficacy and safety of SOF+DCV and SOF+Ribavirin regimens in chronic HCV patients. Although differences were not statistically significant, the study underscores the feasibility of both treatments. Further research is essential for refining strategies and assessing long-term outcomes.

Keywords: Hepatitis C, Sofosbuvir, Daclatasvir, Ribavirin, Treatment Regimens.